Pediatric Cancer Immunotherapy

US News - CancerImmunotherapy is a promising new treatment option for certain kinds of childhood cancers. Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses the body’s own immune system to fight cancer.

Stanford Children’s Health combines cutting-edge immunotherapy research and an experienced team of compassionate doctors to provide the best immunotherapy treatment options for children and young adults with cancer. From KYMRIAH, the first FDA-approved CAR T-cell therapy, to clinical trials only available at Stanford, we offer patients excellent cancer care using the latest therapies.

Our care team includes world-renowned pediatric oncologists, led by Crystal Mackall, MD, who was part of a team at the National Institutes of Health that developed some of the earliest immunotherapy treatments. Our pediatric-specific research program helps us bring cures from the lab bench to the patient’s bedside. As a member of the Pediatric Cancer Immunotherapy Trials Network, we continually collaborate with other doctors and researchers to bring our patients the best possible care.